Related references
Note: Only part of the references are listed.Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma
Kah-Whye Peng et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases
Naohiro Nomura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes
Rumi Sasaki et al.
CARCINOGENESIS (2009)
Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model
Emily K. Mader et al.
CLINICAL CANCER RESEARCH (2009)
Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity
E. J. Ilett et al.
GENE THERAPY (2009)
Current status of gynecologic cancer in Japan
Kimio Ushijima
JOURNAL OF GYNECOLOGIC ONCOLOGY (2009)
Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy
A. T. Power et al.
GENE THERAPY (2008)
Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10
Daisuke Watanabe et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2008)
Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus
Yoko Ushijima et al.
MICROBES AND INFECTION (2007)
Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies
H. T. Ong et al.
GENE THERAPY (2007)
Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions
Ta-Chiang Liu et al.
CANCER RESEARCH (2007)
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity
Anthony T. Power et al.
MOLECULAR THERAPY (2007)
Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy
Ianko D. Iankov et al.
MOLECULAR THERAPY (2007)
Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer
Hideto Kimata et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Recent progress in the battle between oncolytic viruses and tumours
KA Parato et al.
NATURE REVIEWS CANCER (2005)
Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells
C Cole et al.
NATURE MEDICINE (2005)
Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors
J García-Castro et al.
CANCER GENE THERAPY (2005)
Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen
H Kasuya et al.
CANCER RESEARCH (2004)
Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors
D Jevremovic et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2004)
Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus
NK Green et al.
GENE THERAPY (2004)
Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer
A Nakao et al.
ANNALS OF ONCOLOGY (2004)
Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases
Z Raykov et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10
O Teshigahara et al.
JOURNAL OF SURGICAL ONCOLOGY (2004)
Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice
H Takakuwa et al.
ARCHIVES OF VIROLOGY (2003)
Regulation of herpes simplex virus 1 replication using tumor-associated promoters
JT Mullen et al.
ANNALS OF SURGERY (2002)
PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver
MA Croyle et al.
HUMAN GENE THERAPY (2002)
Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients
H Kajiyama et al.
ONCOLOGY (2002)
Recent advancements in the treatment of epithelial ovarian cancer
PJ DiSaia et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2001)
Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients
Y Stallwood et al.
GENE THERAPY (2000)
Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy
G Coukos et al.
CANCER GENE THERAPY (2000)